- Brand: HydreaGeneric: Hydroxyurea
- Brand: DroxiaGeneric: Hydroxyurea Capsules
- Brand: SiklosGeneric: Hydroxyurea Tablets, for Oral Use
- Brand: ZeritGeneric: Stavudine
- Brand: VidexGeneric: Didanosine Pediatric Powder for Oral Solution
- Brand: TibsovoGeneric: Ivosidenib Tablets
- Brand: JakafiGeneric: Ruxolitinib
- Brand: Videx ECGeneric: Didanosine Delayed-Release Capsules
- Brand: IdhifaGeneric: Enasidenib Tablets
Diseases, Conditions, and Procedures
- Polycythemia (High Red Blood Cell Count)Source: MedicineNet
Polycythemia is a condition in which the body's red blood cells are elevated. Primary polycythemia is caused by a changes in the body's JAK2 gene, but what causes this change is not known. Secondary polycythemia is caused by long-term exposure to low oxygen levels (for example, at high altitudes). Symptoms include fatigue, headache, itching, abdominal pain, and joint pain.
- Sickle Cell Disease (Sickle Cell Anemia)Source: MedicineNet
Sickle cell anemia (sickle cell disease) is a blood disease that shortens life expectancy. It is caused by an inherited abnormal hemoglobin that decreases life expectancy. Symptoms of sickle cell anemia include bacterial infections, arthritis, leg ulcers, fatigue, and lung and heart injury. Sickle cell treatment is focused on managing and preventing the worst symptoms of the disease.
- HydroxyureaSource: RxList Medscape
Hydroxyurea is an antineoplastic (anti-cancer) agent used to treat melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and primary squamous cell (epidermoid) carcinomas of the head and neck.
- FDA Approves Jakafi to Treat Bone Marrow DiseaseSource: FDA
The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.
- Sickle Cell Disease: NIH Program Advances Potential TreatmentSource: FDA
A drug candidate developed by researchers at the NIH’s National Center for Advancing Translational Sciences (NCATS) and its collaborators to treat sickle cell disease has been acquired by Baxter International's BioScience business.
- FDA Approves First Drug to Treat MyelofibrosisSource: FDA
The U.S. Food and Drug Administration today approved Jakafi (ruxolitinib), the first drug approved to specifically treat patients with the bone marrow disease myelofibrosis.
- NIH Panel Recommends Expanded Adoption of Sickle Cell DrugSource: FDA
An expert panel has recommended expanded adoption of the drug hydroxyurea for the care of people with sickle cell disease, according to a report issued today. The report also suggests that clinicians give periodic blood transfusions to children with the disease to reduce stroke risk. According to the panel, both treatments are underutilized.